BLUE BELL, Pa.--(BUSINESS WIRE)--June 15, 2006--Locus Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the FDA to begin a Phase I human clinical study of the Company’s lead compound, LP-261, an orally administered small molecule for the treatment of cancer.
